MedTrace Logo

Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.

NCT05421104 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1576

Last updated 2022-07-05

No results posted yet for this study

Summary

This was an analytical and descriptive, non-interventional, retrospective cohort study of PV patients aged ≥ 18 years in the US using a secondary data source, Optum EHR database.

Conditions

  • Polycythemia Vera (PV)

Interventions

OTHER

Ruxolitinib

PV patients who were resistant to or intolerant of HU (as defined on the index date) and switched to RUX in the post-index period.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-27
Primary Completion
2021-06-29
Completion
2021-06-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05421104 on ClinicalTrials.gov